Drug Profile
Tazarotene/ulobetasol - Ortho Dermatologics
Alternative Names: DUOBRII; Halobetasol propionate/tazarotene; IDP-118; Tazarotene/halobetasol propionate; Ulobetasol/tazaroteneLatest Information Update: 29 Dec 2022
Price :
$50
*
At a glance
- Originator Dow Pharmaceutical Sciences
- Developer Ortho Dermatologics
- Class Antipsoriatics; Corticosteroids; Cyclopentanes; Keratolytics; Nicotinic acids; Phenanthrenes; Pyridines; Retinoids; Small molecules
- Mechanism of Action Retinoid X receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Plaque psoriasis
Most Recent Events
- 29 Dec 2022 Launched for Plaque psoriasis in Canada (Topical)
- 02 Dec 2022 US District Court for the District of New Jersey issued a favorable decision for DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US
- 08 Sep 2020 9302085: Added patent info and HE